CLGNEarnings•prnewswire•
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Sentiment:Neutral (45)
Summary
- Sales of rhCollagen and bioinks primed for augmentation following new U.S.-based commercial executive hire - - Raised $3.6 million in registered direct offering in second quarter - REHOVOT, Israel, Aug. 20, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 20, 2025 by prnewswire